Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 4/20 | 0.48 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY4R | P50391 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14886151 | 0.93 | OPRD1 (0.49) | OPRD1NPBWR1OPRK1NPY1RNPY2R | |
| SCHEMBL29702389 | 0.85 | TFPI (0.54) | TFPIOPRD1NPBWR1OPRK1NPY1R | |
| SCHEMBL31114996 | 0.84 | F2 (0.52) | OPRD1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29702470 | 0.83 | TFPI (0.54) | TFPIOPRD1NPBWR1OPRK1NPY1R | |
| SCHEMBL31114999 | 0.82 | TFPI (0.56) | TFPIOPRD1NPBWR1OPRK1NPY1R | |
| SCHEMBL31114990 | 0.82 | NPY4R (0.55) | OPRD1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31688303 | 0.82 | GLP1R (0.56) | TFPIOPRD1OPRK1 | |
| SCHEMBL30900789 | 0.81 | TFPI (0.66) | TFPINPBWR1 | |
| SCHEMBL30900775 | 0.81 | TFPI (0.69) | TFPIOPRD1NPBWR1OPRK1 | |
| SCHEMBL30900786 | 0.81 | TFPI (0.66) | TFPINPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101628-A1 | NOVEL VEGF MIMETIC PEPTIDE-BASED SCAFFOLDS FOR THERAPEUTIC ANGIOGENESIS AND METHODS FOR THEIR USE | NORTHWESTERN UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101628-A1 | NOVEL VEGF MIMETIC PEPTIDE-BASED SCAFFOLDS FOR THERAPEUTIC ANGIOGENESIS AND METHODS FOR THEIR USE | VEGFA, KDR, FLT4 | TFPI 479/4885OPRD1 3873/4885NPBWR1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.